ABVX vs PFE

Abivax SA continues to exhibit significant 10x growth potential, primarily de-risked by obefazimod's positive DSMB review in its Phase 3 UC trial (90% complete, topline late Q2 2026). The substantial €530.4M cash position, secured through a recent offering, provides a runway to Q4 2027, mitigating immediate financial risk. The drug's differentiated oral, first-in-class STAT1 inhibitor profile stil...

Pfizer Inc. remains a mature, large-cap pharmaceutical company with no material changes since the last analysis that would indicate a path to 10x growth. The company faces ongoing headwinds from declining COVID product sales and patent cliffs. While a settlement extended Vyndamax exclusivity, this is insufficient to offset broader challenges. Upcoming Q1 2026 earnings are projected to show a ~20% ...